Sophia Antipolis, France

MEDIAN Technologies (ALMDT), a developer of medical imaging software and provider of services for the interpretation and management of imaging in oncology, has announced its half-yearly results for 2016.

The Board of Directors of MEDIAN Technologies met on October 6, 2016 and approved the consolidated financial statements for the first six months of 2016.

“In the first half of 2016, MEDIAN again recorded a strong growth of its activities in the clinical trials market. MEDIAN also secured major partnerships with the launch of a collaborative project with Microsoft and the extension of the collaboration with START. The first half of 2016 also marked a new stage in the company’s development with the strengthening of the presence in the United States in anticipation of future growth,” saidFredrik Brag, Chief Executive Officer of MEDIAN Technologies


In € thousand (audited)

Income from ordinary operations



Personnel expenses
External expenses (2,560) (1,268)

Operating profit (loss)



Net financial profit (loss) (37) 86

Net profit (loss)




2016 half-yearly results: doubling of revenues and reinforced structure in the United States

MEDIAN Technologies generated €2.9 million in revenues in the first half of 2016, twice the amount from a year earlier. This strong performance reflects sustained business activity in the clinical trials market.

Personnel expenses rose, reflecting a reinforced workforce as new recruits were added over the past year in anticipation of the company’s future growth.

External expenses increased in line with revenue growth, helping to sustain the growth in business and cover costs linked to new order intake.

Over the period, MEDIAN Technologies took measures to reinforce its operational capacities in the United States in an effort to consolidate its position in the management of medical imaging projects for clinical trials.

Alongside these developments, in the first half of 2016 MEDIAN recorded an operating loss of -€3.6 million and a net loss of -€3.7 million, in line with the company’s expectations.

As of June 30, 2016, MEDIAN Technologies had a solid balance sheet and €26.5 million in net cash. Its equity amounted to €23.0 million.

Outlook: sustained sales momentum

MEDIAN Technologies’ reinforced presence on the clinical trials market enables the company to pursue its expansion policy, targeting new clients among Big Pharma and biotech companies.

As of June 30, 2016, MEDIAN Technologies’ order backlog* stood at €21 million, compared to €18 million one year earlier, representing a growth of 17%. The order backlog was stable from 31 December 2015, as some contracts were cancelled following internal restructuring by one of MEDIAN’s clients. This cancellation was offset by new businesses.

The half-yearly financial report is available on the company’s

Financial calendar: Publication of 2016 annual results – April 12, 2017

(*) Order backlog refers to customer orders that have been received but not yet invoiced.

Download 20161012_HalfYearly_Results.pdf

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”


MEDIAN Technologies

Fredrik Brag
+33 4 92 90 65 82

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66